Therapeutic Research

Abstract

Background：Meropenem is used as a first‒line drug for severe infections such as septic shock and intra‒abdominal infections, but the high incidence of drug‒induced liver injury（DILI）is a clinical issue. 　　Objective：The purpose of this study was to identify the risk factors for DILI induced by meropenem based on patient information. 　Method：Patients treated with meropenem were retrospectively selected. Univariate analysis and multivariate logistic regression analysis between patients with DILI and those without DILI（non‒DILI）were performed for age, gender, dose, duration of administration and clinical laboratory values immediately before the start of treatment. 　Results：CRP（odds ratio：1.144, 95％ confidence interval：1.031‒1.269, p＝0.011） before the administration of meropenem was extracted as a risk factor for DILI. 　Conclusion：Consideration of the possibility of treatment with other antimicrobials or closer monitoring of liver function when meropenem is administered in patient with elevated CRP may help prevent the incidence and severity of DILI.